The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist
Open accessAbstract
Context: Cotadutide is a dual receptor agonist with balanced glucagon-like peptide-1 and glucagon activity. Objective: To evaluate different doses of cotadutide and investigate underlying mechanisms for its glucose-lowering effects. Design/setting: Randomized, double-blind, phase 2a study conducted in 2 cohorts at 5 clinical trial sites. Patients: Participants were 65 adult overweight/obese patients with type 2 diabetes mellitus; 63 completed the study; 2 were withdrawn due to AEs. Intervention: Once-daily subcutaneous cotadutide or placebo for 49 days. Doses (50–300 µg) were uptitrated weekly (cohort 1) or biweekly (cohort 2). Main outcome measures: Co-primary end points (cohort 1) were percentage changes from baseline to end of treatment in glucose (area under the curve from 0 to 4 hours [AUC0–4h]) post–mixed-meal tolerance test (MMTT) and weight. Exploratory measures included postprandial insulin and gastric emptying time (GET; cohort 2). Results: Patients received cotadutide (cohort 1, n = 26; cohort 2, n = 20) or placebo (cohort 1, n = 13; cohort 2, n = 6). Significant reductions were observed with cotadutide vs placebo in glucose AUC0–4h post MMTT (least squares mean [90% CI], −21.52% [−25.68, −17.37] vs 6.32% [0.45, 12.20]; P < 0.001) and body weight (−3.41% [−4.37, −2.44] vs −0.08% [−1.45, 1.28]; P = 0.002). A significant increase in insulin AUC0–4h post MMTT was observed with cotadutide (19.3 mU.h/L [5.9, 32.6]; P = 0.008) and GET was prolonged on day 43 with cotadutide vs placebo (t½: 117.2 minutes vs −42.9 minutes; P = 0.0392). Conclusion: These results suggest that the glucose-lowering effects of cotadutide are mediated by enhanced insulin secretion and delayed gastric emptying. Trial Registration: ClinicalTrials.gov, NCT03244800.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical research on GLP-1/ glucagon receptor co-agonists also reveals clear decreases in amino acid levels (Parker et al, 2020;Simonsen et al, 2022).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Parker et al, 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical research on GLP-1/ glucagon receptor co-agonists also reveals clear decreases in amino acid levels (Parker et al, 2020;Simonsen et al, 2022).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Parker et al, 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“data from clinical trials of once-daily GLP-1R/GcgR co-agonists cotadutide (previously MEDI0382) [[21], [22], [23]] and SAR425899 [24,25] have generated guarded optimism over the modest effects on weight reduction (<10% after 4–6 weeks of treatment)”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cotadutide effectively lowered blood sugar levels and reduced weight in obese individuals and T2DM patients, increased insulin secretion, delayed gastric emptying, with the most common side effects being gastrointestinal symptoms (nausea and vomiting), which were dose-dependent [99,100].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [100]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There were two further phase IIa studies evaluating cotadutide with the first one showing that it reduced glucose levels in those with obesity and T2DM with the mechanism being greater insulin secretion and delayed gastric emptying [46].”
From The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. (2024) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of Medical Care in Diabetes
Power, D. V. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,676
Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
Zheng, Y., Ley, S. H., & Hu, F. B. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.151 · Cited by 5,697
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 5×
“Glucagon-like peptide-1 (GLP-1) receptor agonists are established therapies for T2DM and provide effective glycemic control and modest weight loss (8).”
BackgroundInfluentialSelf-citationRegulation of hepatic glucose metabolism in health and disease
Petersen, M. C., Vatner, D. F., & Shulman, G. I. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.80 · Cited by 1,159
Glucagon and regulation of glucose metabolism
Jiang, G., & Zhang, B. B. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00492.2002 · Cited by 905
Standards of Medical Care in Diabetes
(2004) · Diabetes Care · doi:10.2337/diacare.27.2007.s15 · Cited by 688
IDF Diabetes Atlas 9th Edition
Diabetes Federation (2019) · Cited by 586
Abell, T. L., Camilleri, M., Donohoe, K. J., Hasler, W. L., Lin, H. C., Maurer, A. H., McCallum, R. W., Nowak, T. V., Nusynowitz, M. L., Parkman, H. P., et al. (2008) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.107.048116 · Cited by 441
Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435
The metabolic actions of glucagon revisited
Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.187 · Cited by 406
Cited by
Sorted by citations
G protein-coupled receptors: structure- and function-based drug discovery
Yang, D., Zhou, Q., Labroska, V., Qin, S., Darbalaei, S., Wu, Y., Yuliantie, E., Xie, L., Tao, H., Cheng, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00435-w · Cited by 684
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323
Self-citationGlucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 315
Self-citationEffects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
Metabolic messengers: glucagon-like peptide 1
Gribble, F. M., & Reimann, F. (2021) · Nature Metabolism · doi:10.1038/s42255-020-00327-x · Cited by 199
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 152
Kloock, S., Ziegler, C. G., & Dischinger, U. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108549 · Cited by 173
Blüher, M., Rosenstock, J., Hoefler, J., Manuel, R., & Hennige, A. M. (2024) · Diabetologia · doi:10.1007/s00125-023-06053-9 · Cited by 138
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Sinha, R., Papamargaritis, D., Sargeant, J. A., & Davies, M. J. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22067 · Cited by 138
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angelidi, A. M., Belanger, M. J., Kokkinos, A. D., Koliaki, C. C., & Mantzoros, C. S. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab034 · Cited by 141
An update on peptide-based therapies for type 2 diabetes and obesity
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2023) · Peptides · doi:10.1016/j.peptides.2023.170939 · Cited by 111
Nutrient-Induced Cellular Mechanisms of Gut Hormone Secretion
Lu, V. B., Gribble, F. M., & Reimann, F. M. (2021) · Nutrients · doi:10.3390/nu13030883 · Cited by 111
Targeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 110
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00812-z · Cited by 102
Hiramoto, B. A., McCarty, T. R., Lodhia, N. A., Jenkins, A., Elnaiem, A. D., Muftah, M., Flanagan, R. F., & Chan, W. W. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002820 · Cited by 109
Emerging pharmacotherapies for obesity: A systematic review
Kokkorakis, M., Chakhtoura, M., Rhayem, C., Al Rifai, J., Ghezzawi, M., Valenzuela-Vallejo, L., & Mantzoros, C. S. (2025) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001045 · Cited by 102
Tschöp, M., Nogueiras, R., & Ahrén, B. (2023) · Diabetologia · doi:10.1007/s00125-023-05929-0 · Cited by 92
Labeling and Characterization of Human GLP-1-Secreting L-cells in Primary Ileal Organoid Culture
Goldspink, D. A., Lu, V. B., Miedzybrodzka, E. L., Smith, C. A., Foreman, R. E., Billing, L., Kay, R. G., Reimann, F. M., & Gribble, F. M. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107833 · Cited by 95
Striking the balance: GLP-1/glucagon co-agonism as a treatment strategy for obesity
Hope, D. C. D., Vincent, M. L., & Tan, T. M. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.735019 · Cited by 81
The molecular pharmacology of glucagon agonists in diabetes and obesity
Novikoff, A., & Müller, T. D. (2023) · Peptides · doi:10.1016/j.peptides.2023.171003 · Cited by 82
Parker, V. E. R., Hoang, T., Schlichthaar, H., Gibb, F. W., Wenzel, B., Posch, M. G., Rose, L., Chang, Y., Petrone, M., Hansen, L., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14712 · Cited by 80
Self-citationHow glucagon-like peptide 1 receptor agonists work
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Endocrine Connections · doi:10.1530/ec-21-0130 · Cited by 71
Proglucagon-Derived Peptides as Therapeutics
Lafferty, R. A., O'Harte, F. P. M., Irwin, N., Gault, V. A., & Flatt, P. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.689678 · Cited by 76
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Hepatic glucagon action: beyond glucose mobilization
Kajani, S., Laker, R. C., Ratkova, E. L., Will, S., & Rhodes, C. J. (2024) · Physiological Reviews · doi:10.1152/physrev.00028.2023 · Cited by 65
Parker, V. E. R., Robertson, D., Erazo-Tapia, E., Havekes, B., Phielix, E., de Ligt, M., Roumans, K. H. M., Mevenkamp, J., Sjoberg, F., Schrauwen-Hinderling, V. B., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00938-0 · Cited by 53
Self-citationPharmacotherapy of obesity: An update
Cignarella, A., Busetto, L., & Vettor, R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105649 · Cited by 58
Selvarajah, V., Robertson, D., Hansen, L., Jermutus, L., Smith, K., Coggi, A., Sánchez, J., Chang, Y.-T., Yu, H., Parkinson, J., et al. (2024) · Kidney International · doi:10.1016/j.kint.2024.08.023 · Cited by 49
Self-citationJakubowska, A., Roux, C. W. L., & Viljoen, A. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1942 · Cited by 45
Sztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024) · Biomedicines · doi:10.3390/biomedicines12061320 · Cited by 47
“Cotadutide effectively lowered blood sugar levels and reduced weight in obese individuals and T2DM patients, increased insulin secretion, delayed gastric emptying, with the most common side effects being gastrointestinal symptoms (nausea and vomiting), which were dose-dependent [99,100].”
BackgroundGlucagon in type 2 diabetes: Friend or foe?
Caruso, I., Marrano, N., Biondi, G., Genchi, V. A., D'Oria, R., Sorice, G. P., Perrini, S., Cignarelli, A., Natalicchio, A., Laviola, L., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3609 · Cited by 35
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
Abdelmalek, M. F., Harrison, S. A., & Sanyal, A. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15524 · Cited by 45
Winther, J. B., & Holst, J. J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15693 · Cited by 47
Cryo-electron microscopy structure of the glucagon receptor with a dual-agonist peptide
Chang, R., Zhang, X., Qiao, A., Dai, A., Belousoff, M. J., Tan, Q., Shao, L., Li, Z., Lin, G., Liang, Y.-L., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013793 · Cited by 39
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 42
Asano, M., Sekikawa, A., Kim, H., Gasser, R. A., Robertson, D. C., Petrone, M., Jermutus, L., & Ambery, P. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14412 · Cited by 40
Self-citationEvaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors
Darbalaei, S., Yuliantie, E., Dai, A., Chang, R., Zhao, P., Yang, D., Wang, M.-W., Sexton, P. M., & Wootten, D. L. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114150 · Cited by 35
Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss
Hope, D. C. D., Hinds, C. E., Lopes, T., Vincent, M. L., Shrewsbury, J. V., Yu, A. T. C., Davies, I., Scott, R., Jones, B., Murphy, K. G., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100810 · Cited by 32
Block, C. E. M. D., Dirinck, E. L., Verhaegen, A. A., & Gaal, L. F. V. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14640 · Cited by 33
Jiang, Y., Zhu, H., & Gong, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16106 · Cited by 35
Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
Gong, B., Yao, Z., Zhou, C., Wang, W., Sun, L., & Han, J. D. J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116342 · Cited by 29
Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome
Αλεξιάδου, Κ., & Tan, T. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01309-9 · Cited by 26
Glucagon and Its Receptors in the Mammalian Heart
Neumann, J., Hofmann, B., Dhein, S., & Gergs, U. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612829 · Cited by 31
Newer pharmacological interventions directed at gut hormones for obesity
Camilleri, M., & Acosta, A. J. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16278 · Cited by 28
Ali, M. M., Hafez, A., Abdelgalil, M. S., Hasan, M. T., El-Ghannam, M. M., Ghogar, O. M., Elrashedy, A. A., & Abd-ElGawad, M. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01031-5 · Cited by 23
The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon
Spezani, R., & Mandarim-de-Lacerda, C. A. (2022) · Life Sciences · doi:10.1016/j.lfs.2021.120188 · Cited by 23
Muzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 24
Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy
Khoo, B. C. E., & Tan, T. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0119 · Cited by 23
Binsila, B. K., Archana, S. S., Ramya, L., Swathi, D., Selvaraju, S., Gowda, N. S., Pal, D. T., Rafay, A., & Bhatta, R. (2020) · Cell and Tissue Research · doi:10.1007/s00441-020-03303-9 · Cited by 22
Valdecantos, M. P., Ruiz, L., Folgueira, C., Rada, P., Gómez‐Santos, B., Solas, M., Hitos, A. B., Field, J., Francisco, V., Escalona-Garrido, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54080-w · Cited by 24
Self-citationCamilleri, M. (2023) · Neurogastroenterology & Motility · doi:10.1111/nmo.14660 · Cited by 24
The role of incretin receptor agonists in the treatment of obesity
Forst, T. M., Block, C. E. M. D., Prato, S. D., Armani, S., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15796 · Cited by 20
Examining the evidence for weight management in individuals with type 2 diabetes
Garvey, W. T., Umpierrez, G. E., Dunn, J. P., Kwan, A. Y. M., Varnado, O. J., Konig, M., & Levine, J. A. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14764 · Cited by 18
Incretin based therapy and pancreatic cancer: Realising the reality
Suryadevara, V., Roy, A., Sahoo, J., Kamalanathan, S., Naik, D., Mohan, P., & Kalayarasan, R. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i25.2881 · Cited by 22
Zhihong, Y., Chen, W., Qianqian, Z., Lidan, S., Zhou, Q., Han, J. D. J., Wenxi, W., & Bhawal, R. P. (2023) · Peptides · doi:10.1016/j.peptides.2023.170955 · Cited by 17
Golubić, R., Kennet, J., Parker, V., Robertson, D. C., Luo, D., Hansen, L. B., Jermutus, L., Ambery, P., Ryaboshapkina, M., Surakala, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15579 · Cited by 19
Self-citationJohansson, K. S., Sonne, D. P., Knop, F. K., & Christensen, M. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1791078 · Cited by 17
Kakouri, A., Kanti, G., Kapantais, E., Kokkinos, A. D., Lanaras, L., Farajian, P., Galanakis, C., Georgantopoulos, G., Vlahos, N., Mastorakos, G. P., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14090869 · Cited by 17
Population Pharmacokinetics of Cotadutide in Subjects with Type 2 Diabetes
Ye, G., Ly, N. S., Li, J., & Arends, R. H. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01094-y · Cited by 16
Xie, Y., Zhou, Q., He, Q., Wang, X., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.008 · Cited by 16
Cotadutide effect in liver and adipose tissue in obese mice
Marcondes‐de‐Castro, I. A., Oliveira, T. F., Spezani, R., Marinho, T. D. S., Cardoso, L. E. M., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2023) · Journal of Molecular Endocrinology · doi:10.1530/jme-22-0168 · Cited by 17
Hope, D. C. D., & Tan, T. M.-M. (2023) · Peptides · doi:10.1016/j.peptides.2023.170962 · Cited by 16
Deng, B., Ruan, T., Lu, W., Ying, J., Li, S., Zhou, R., & Mu, D. (2024) · Endocrine · doi:10.1007/s12020-024-03857-6 · Cited by 15
Patil, M., Casari, I., Warne, L. N., & Falasca, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116245 · Cited by 12
Laker, R. C., Egolf, S., Will, S., Lantier, L., McGuinness, O. P., Brown, C. L., Bhagroo, N. V., Oldham, S. N., Kuszpit, K. K., Alfaro, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59773-4 · Cited by 15
Asano, M., Sekikawa, A., Sugeno, M., Matsuoka, O., Robertson, D. C., & Hansen, L. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15107 · Cited by 13
Self-citationPopulation pharmacokinetic of paracetamol and atorvastatin with co‐administration of semaglutide
Langeskov, E. K., & Kristensen, K. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.962 · Cited by 12
Bosch, R., Petrone, M., Arends, R., Vicini, P., Sijbrands, E. J. G., Hoefman, S., & Snelder, N. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12752 · Cited by 11
Self-citationPerspectives in weight control in diabetes – SGLT2 inhibitors and GLP-1–glucagon dual agonism
Iqbal, N., Ambery, P., Logue, J., Mallappa, A., & Sjöström, C. D. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110669 · Cited by 13
Self-citationOXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes
Melander, S. A., Kayed, A., Andreassen, K. V., Karsdal, M. A., & Henriksen, K. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176215 · Cited by 11
Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot?
McGlone, E. R., & Tan, T. (2024) · Peptides · doi:10.1016/j.peptides.2024.171219 · Cited by 11
Incretin-based therapy: a new horizon in diabetes management
Zarei, M., Vaighan, N. S., Farjoo, M. H., Talebi, S., & Zarei, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01479-3 · Cited by 12
Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
Vishnoi, S., Bhattacharya, S., Walsh, E. M., Okoh, G., & Thompson, D. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00752 · Cited by 12
Bosch, R., Petrone, M., Arends, R., Vicini, P., Sijbrands, E. J. G., Hoefman, S., & Snelder, N. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16336 · Cited by 10
Self-citationCazac, G.-D., Lăcătușu, C.-M., Grigorescu, E.-D., Foșălău, A.-B., Onofriescu, A., & Mihai, B. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041042 · Cited by 10
Stachteas, P., Nasoufidou, A., Karakasis, P., Koiliari, M., Karagiannidis, E., Koufakis, T., Fragakis, N., & Patoulias, D. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm39691 · Cited by 11
Darbalaei, S., Chang, R., Zhou, Q., Chen, Y., Dai, A., Wang, M., & Yang, D. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00962-y · Cited by 9
Conlon, J. M., O'Harte, F. P. M., & Flatt, P. R. (2021) · Peptides · doi:10.1016/j.peptides.2021.170706 · Cited by 9
Novel Drugs for Diabetes Therapy
Heise, T. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2021_574 · Cited by 11
Self-citationCazac, G.-D., Lăcătușu, C.-M., Ștefănescu, G., Mihai, C., Grigorescu, E.-D., Onofriescu, A., & Mihai, B. M. (2023) · Metabolites · doi:10.3390/metabo13050581 · Cited by 10
Chee, Y. J., & Dalan, R. (2024) · Biomedicines · doi:10.3390/biomedicines12071386 · Cited by 7
Corrao, S., Falcone, F., Mirarchi, L., Amodeo, S., & Calvo, L. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01761-4 · Cited by 9
Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare
Bhat, S., Fernandez, C. J., Lakshmi, V., & Pappachan, J. M. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i8.107991 · Cited by 9
Klein, G., Petrone, M., Yang, Y., Hoang, T., Hazlett, S., Hansen, L. B., & Flor, A. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01239-1 · Cited by 7
Self-citationWinther‐Sørensen, M., García, S. L., Bartholdy, A., Ottenheijm, M. E., Banasik, K., Brunak, S., Sørensen, C. M., Gluud, L. L., Knop, F. K., Holst, J. J., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06160-1 · Cited by 8
Hope, D. C. D., Ansari, S., Choudhury, S., Αλεξιάδου, Κ., Tabbakh, Y., Ilesanmi, I., Lazarus, K., Davies, I., Jimenez‐Pacheco, L., Yang, W. P., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15448 · Cited by 6
Camilleri, M. (2024) · The Journal of Physiology · doi:10.1113/jp287535 · Cited by 7
Lindsay, R. T., Ambery, P., Jermutus, L., & Murray, A. J. (2023) · Physiological Reports · doi:10.14814/phy2.15597 · Cited by 5
Self-citationYu, H., Åstrand, M., Cheng, J. Y., Nitin, K., Hamrén, B., & Khan, A. A. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01337-0 · Cited by 4
Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists
Zhang, X., Cai, Y., Yao, Z., Chi, H., Li, Y., Shi, J., Zhou, Z., & Sun, L. (2023) · Peptides · doi:10.1016/j.peptides.2023.170948 · Cited by 4
Wang, J., Chen, X., & Zhao, Y. (2023) · PubMed Central · Cited by 4
Prieto, B. L. A., & Lozano, E. W. M. (2001) · Repositorio Institucional Universidad Católica de Colombia (Universidad Católica de Colombia) · Cited by 4
Kamrul-Hasan, A. B. M., Dutta, D., Nagendra, L., Basavarajappa, S. D., Girijashankar, H. B., Joshi, A., & Pappachan, J. M. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i12.112830 · Cited by 4
Druzhilov, М. A., Kuznetsova, Т. Y., & Chumakova, G. A. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-4755 · Cited by 4
Odongo, K., Ishinaka, M., Abe, A., Harada, N., Yamaji, R., Yamashita, Y., & Ashida, H. (2025) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202400690 · Cited by 2
Glucagon and the metabolic syndrome
Welch, A., & Vella, A. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00011-6 · Cited by 1
Bosch, R., Petrone, M., Arends, R., Sijbrands, E. J. G., Hoefman, S., & Snelder, N. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70074 · Cited by 1
Self-citationImpact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 1
Metadata
- Authors
- Parker, V. E. R., Robertson, D., Wang, T., Hornigold, D. C., Petrone, M., Cooper, A. T., Posch, M. G., Heise, T., Plum-Moerschel, L., Schlichthaar, H., Klaus, B., Ambery, P. D., Meier, J. J., & Hirshberg, B.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (United States) (US)
- Charité – Universitätsmedizin Berlin (DE)
- Profil Institute for Metabolic Research (DE)
- Profil, Mainz, Germany
- SMO.MD, Magdeburg, Germany
- Nuvisan (Germany) (DE)
- AstraZeneca, Gothenburg, Sweden
- St. Josef-Hospital (DE)
- Corresponding author
- Parker, Victoria E R
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2019-10-14
- Volume
- 105
- Issue
- 3
- Pages
- 803-820
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2981305821
- Cited by
- 123
- References
- 37
- Citations by year
- 2026: 12 · 2025: 9 · 2024: 27 · 2023: 30 · 2022: 14 · 2021: 19 · 2020: 11
- FWCI
- 8.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca. V. Ruvini Jayasinghe
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- cotadutide, dual receptor agonist, glucagon-like peptide-1, glucagon, type 2 diabetes, obesity, glucose-lowering effect, postprandial insulin, gastric emptying, weight loss, mixed meal tolerance test, dose escalation, drug safety, adverse events, GLP-1 receptor, GIP receptor, incretin-based therapy, pharmacokinetics
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Follow-Up Studies, Glucagon, Humans, Male, Middle Aged, Obesity, Peptides, Prognosis, Biomarkers, Receptors, Glucagon, Overweight, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
